Geneva Capital Management LLC Sells 5,890 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Geneva Capital Management LLC lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 12.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,330 shares of the company’s stock after selling 5,890 shares during the period. Geneva Capital Management LLC owned about 0.05% of IDEXX Laboratories worth $17,914,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth about $25,000. Retirement Wealth Solutions LLC bought a new position in IDEXX Laboratories during the 4th quarter worth about $31,000. Ashton Thomas Securities LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth about $37,000. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $38,000. Finally, Crews Bank & Trust acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $41,000. Institutional investors own 87.84% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on IDXX. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Thursday, February 27th. Piper Sandler increased their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Morgan Stanley reduced their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Bank of America increased their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Trading Down 1.0 %

Shares of NASDAQ:IDXX opened at $437.23 on Thursday. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $574.94. The company has a market capitalization of $35.56 billion, a P/E ratio of 40.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company has a 50-day simple moving average of $436.83 and a 200 day simple moving average of $450.33. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.